Delito (rituximab biosimilar) / Sino Biopharm - LARVOL DELTA

LEY INTERRUPCIO?N VOLUNTARIA DEL EMBARAZO CARACTERIZACIO?N A 5 AN?OS DE SU IMPLEMENTACIO?N EN CHILE (FIGO 2025) - "Conclusión: Se observa que la causal de riesgo de vida de la madre es la principal razón de constitución e interrupción de embarazos en Chile, seguida por la inviabilidad fetal y en último lugar la causal de violación. Se destaca que las mujeres adultas tienen mayor tasa de interrupción que las adolescentes y las niñas – quienes acceden a esta prestación en consecuencia de delitos de violación. Esto evidencia inequidades en la implementación de la IVE y sugiere la necesidad de mayores investigaciones sobre los desafios especificos que enfrentan las niñas al decidir sobre sus embarazos."

La eliminación del delito de aborto: el liderazgo de los profesionales de la salud (FIGO 2025) - No abstract available

"Esa ley no es penal, no se si es delito. Por otro lado los periodistas tienen la chapa para preservar la fuente" (@alerosenfeld)

"No es por protección de nadie Es puramente por trámites administrativos Lo del delito es una invención suya" (@Juan_A_Alonso)

"El sistema ni es ni deberia ser punitivista... Una ley es mejor no por penas mas duras sino por evitar que los delitos se repitan, por incluir casos de manera mas eficaz, por un enfoque mejor de como tratar los casos.... No por meter 3 o 4 años a una persona en la carcel" (@katapiro)

"El problema es que la fiesta comienza mucho antes de su fecha, sin control, sin amparo legal, donde incluso se esconden delitos y que perjudica a colectivos invisibilizados." (@sorolloff)

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (clinicaltrials.gov) - P2; N=40; Recruiting; Sponsor: M.D. Anderson Cancer Center; Not yet recruiting ➔ Recruiting

Checkpoint inhibition • Clinical • Enrollment open • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia (clinicaltrials.gov) - P2; N=60; Recruiting; Sponsor: M.D. Anderson Cancer Center; Trial completion date: Oct 2020 ➔ Dec 2034; Trial primary completion date: Oct 2020 ➔ Dec 2034

Clinical • Trial completion date • Trial primary completion date • Hematological Malignancies • Leukemia • Oncology

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation (clinicaltrials.gov) - P2; N=44; Recruiting; Sponsor: M.D. Anderson Cancer Center; Trial completion date: Mar 2021 ➔ Mar 2025; Trial primary completion date: Mar 2021 ➔ Mar 2025

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Lymphoma • Oncology • Transplantation • CD22 • HLA-DRB1

Venetoclax, Dasatinib, Prednisone, and Rituximab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1; N=20; Not yet recruiting; Sponsor: OHSU Knight Cancer Institute; Initiation date: May 2021 ➔ Aug 2021

Clinical • Combination therapy • Trial initiation date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - P1; N=54; Not yet recruiting; Sponsor: National Cancer Institute (NCI)

Clinical • New P1 trial • Diffuse Large B Cell Lymphoma • Human Immunodeficiency Virus • Infectious Disease • CD20 • CD4

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - P1; N=54; Not yet recruiting; Sponsor: National Cancer Institute (NCI); Trial completion date: Sep 2020 ➔ Jul 2023; Trial primary completion date: Sep 2020 ➔ Jul 2023

Clinical • Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CD4

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - P1; N=54; Recruiting; Sponsor: National Cancer Institute (NCI); Not yet recruiting ➔ Recruiting; Trial primary completion date: Jul 2023 ➔ Sep 2021

Clinical • Enrollment open • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CD4

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: M.D. Anderson Cancer Center; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Chronic Myelomonocytic Leukemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Non-Hodgkin’s Lymphoma • Oncology • Plasmacytoma • Small Lymphocytic Lymphoma • Transplantation • ASXL1 • DNMT3A • FLT3 • KMT2A • PHF6 • TET2

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (clinicaltrials.gov) - P2/3; N=351; Recruiting; Sponsor: National Cancer Institute (NCI); Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • MYC

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - P1; N=54; Recruiting; Sponsor: National Cancer Institute (NCI); Suspended ➔ Recruiting

Clinical • Enrollment open • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CD4

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas (clinicaltrials.gov) - P1; N=54; Suspended; Sponsor: National Cancer Institute (NCI); Recruiting ➔ Suspended

Clinical • Trial suspension • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20 • CD4

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma (clinicaltrials.gov) - P2; N=54; Active, not recruiting; Sponsor: M.D. Anderson Cancer Center; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • CD20 • MYC • TP53

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: M.D. Anderson Cancer Center

Clinical • New P1 trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Chronic Lymphocytic Leukemia • Chronic Myeloid Leukemia • Chronic Myelomonocytic Leukemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Non-Hodgkin’s Lymphoma • Oncology • Plasmacytoma • Small Lymphocytic Lymphoma • Transplantation • ASXL1 • DNMT3A • FLT3 • KMT2A • PHF6 • TET2

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (clinicaltrials.gov) - P2; N=40; Not yet recruiting; Sponsor: M.D. Anderson Cancer Center

Clinical • Combination therapy • New P2 trial • Oncology • BCL2

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (clinicaltrials.gov) - P2/3; N=351; Not yet recruiting; Sponsor: National Cancer Institute (NCI)

Clinical • New P2/3 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • BCL2 • BCL6 • MYC

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P2; N=80; Recruiting; Sponsor: M.D. Anderson Cancer Center; N=60 ➔ 80

Clinical • Enrollment change • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Oncology

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (clinicaltrials.gov) - P2; N=40; Not yet recruiting; Sponsor: M.D. Anderson Cancer Center

Checkpoint inhibition • Clinical • New P2 trial • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TNFRSF8

Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: M.D. Anderson Cancer Center; Trial completion date: Feb 2020 ➔ Nov 2020; Trial primary completion date: Feb 2020 ➔ Nov 2020

Clinical • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Anemia • Aplastic Anemia • Chronic Lymphocytic Leukemia • Chronic Myelomonocytic Leukemia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Non-Hodgkin’s Lymphoma • Oncology • Plasmacytoma • Small Lymphocytic Lymphoma • Transplantation • ASXL1 • DNMT3A • FLT3 • KMT2A • PHF6 • TET2

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (clinicaltrials.gov) - P1/2; N=122; Not yet recruiting; Sponsor: M.D. Anderson Cancer Center

Clinical • Combination therapy • New P1/2 trial • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Myelomonocytic Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • T Acute Lymphoblastic Leukemia • ALB • FLT3 • NPM1